Evidence map›Paper›PMID 41102548›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

Acetylcarnitine in cerebrospinal fluid and blood as a protective factor for neuromyelitis optica spectrum disorders: a mendelian randomization study.

Zhuxiao Xie, Feng Gai, Lei Liu, Yanjun Guo, Hanqiu Jiang, Weijiao Zhang, Jiawei Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Zhuxiao XieDepartment of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Feng GaiDepartment of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Lei LiuDepartment of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Yanjun GuoDepartment of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Hanqiu JiangDepartment of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Weijiao ZhangDepartment of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing, China.
Jiawei WangDepartment of Neurology, Beijing Tongren Hospital, Capital Medical University, Beijing, China. wangjwcq@163.com.ORCID http://orcid.org/0000-0002-4716-928X

Funding

Capital Health Research and Development of Special Fund 2020-2-2056National Natural Science Foundation of China 82271384
6 · The paper itself

Abstract

backgroundNeuromyelitis Optica Spectrum Disorders (NMOSD) are a group of diseases that can cause vision loss and paralysis. Some patients with refractory NMOSD continue to experience relapses or even disability after existing treatments, so it is crucial to further investigate the targets for precision therapy. The link between cerebrospinal fluid (CSF) and blood metabolites and the pathogenesis of NMOSD remains underexplored.

methodsWe conducted a two-sample mendelian randomization (MR) study. Instrumental variables related to 338 CSF metabolites and 486 blood metabolites were extracted from genome-wide association (GWAS) data involved European individuals. A series of sensitivity analyses were applied, including the Cochran Q test, MR-Egger intercept test, MR-PRESSO, and leave-one-out method. Finally, we conducted functional enrichment analysis within MetaboAnalyst 5.0.

resultsWe identified 20 CSF metabolites and 11 blood metabolites indicated causality with NMOSD. We observed a protective effect of acetylcarnitine within NMOSD, both in CSF (OR = 0.47, P value = 7.088 × 10

conclusionThis is the first MR analysis to investigate the causality of CSF and blood metabolites in NMOSD. Acetylcarnitine was a protective factor for NMOSD, with a promising prospect for the treatment of refractory NMOSD. Several other key CSF and blood metabolites could also serve as the candidate molecules for exploring mechanisms and potential drug targets.

Indexed as

AcetylcarnitineNeuromyelitis OpticaBiomarkersGenome-Wide Association StudyHumansMendelian Randomization AnalysisAcetylcarnitineBiomarkersAcetylcarnitineMendelian randomizationMetabolitesNeuromyelitis optica spectrum disorders

Identifiers

PMID41102548

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.